Comparative Pharmacology
Head-to-head clinical analysis: KOVANAZE versus PBZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KOVANAZE versus PBZ.
KOVANAZE vs PBZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KOVANAZE (norepinephrine and phenylephrine) is a combination of two vasopressors: norepinephrine, an α1-adrenergic receptor agonist with β1-adrenergic activity, and phenylephrine, a selective α1-adrenergic receptor agonist. Both agents cause vasoconstriction and increase blood pressure via activation of α1-adrenergic receptors on vascular smooth muscle.
PBZ (phenylbutazone) is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis. It also has uricosuric effects.
Intravenous bolus of 1 mg/kg over 10 minutes, followed by intravenous infusion of 0.02 mg/kg/min for 4 hours, then 0.01 mg/kg/min for 20 hours.
25-50 mg orally every 4-6 hours as needed; not to exceed 300 mg/day. For severe allergies: 25 mg intramuscularly or intravenously every 4-6 hours.
None Documented
None Documented
Terminal elimination half-life: approximately 7-9 hours following nasal administration; clinical significance: supports twice-daily dosing regimen
Terminal elimination half-life: 8-12 hours in adults; prolonged in renal impairment (up to 24 hours).
Renal excretion of unchanged drug: ~20-30%; fecal/biliary elimination: minimal (<5%); remainder as metabolites
Renal excretion of unchanged drug (approximately 70-80%) with the remainder as metabolites. Biliary/fecal excretion accounts for <5%.
Category C
Category C
Antihistamine + Corticosteroid Combination
Antihistamine